FindTrial
Sign In

A study to see the effects of two drugs metronidazole and tacrolimus steroid induced rosacea.

Comparative study of efficacy and safety profile of topical Metronidazole and topical Tacrolimus in Steroid induced Rosacea in tertiary care teaching hospital Haldwani

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025629
Enrollment
60
Registered
2020-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

Interventions

Intervention1: Topical metronidazole gel 0.075%: 12 hourly a day for topical application for 8 weeks Intervention2: Tacrolimus cream 0.03%: 12 hourly a day for topical application for 8 weeks

Sponsors

Government medical collage Haldwani
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either sex with steroid induced rosacea. 2.Age 18 years and above.

Exclusion criteria

Exclusion criteria: 1.Pregnant and Lactating Women. 2.Drug allergy . 3. Children less than 18 years 4.Patients with systemic disease.

Design outcomes

Primary

MeasureTime frame
1.To compare the efficacy of 0.75% metronidazole gel and 0.03% tacrolimus cream in steroid induced rosacea.Timepoint: The patients will be followed up on 1st, 3rd, 5th and 8th week—

Secondary

MeasureTime frame
1. To Study the adverse effects of 0.75% metronidazole gel and 0.03% tacrolimus cream. 2. To study the cost of the therapy. Timepoint: The patients will be followed up on 1st, 3rd, 5th and 8th week.—

Countries

India

Contacts

Public ContactDr Bhavana srivastava

Government Medical College, Haldwani

drsbhavana@gmail.com7895782824

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026